Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
AK-0610 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
AK-0610: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ETNK2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ETNK2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
SYHA-1815 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
SYHA-1815: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ETNK1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ETNK1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
MK-7762 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
MK-7762: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ETHE1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ETHE1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
GMA-106 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
GMA-106: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ETFRF1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ETFRF1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
JADE-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
JADE-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ETFDH Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ETFDH, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Recombinat FGF21-Fc fusion Protein(Ampsource Biopharma) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Recombinat FGF21-Fc fusion Protein(Ampsource Biopharma): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
ETFBKMT Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ETFBKMT, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.